Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sanara MedTech ( (SMTI) ) has issued an update.
On May 19, 2025, Michael D. McNeil announced his retirement from his roles as Chief Accounting Officer and Chief Administrative Officer at Sanara MedTech Inc., effective August 19, 2025. The company is in discussions with McNeil for a consulting role to aid in the transition. Elizabeth B. Taylor, the current Chief Financial Officer, will take over McNeil’s responsibilities as the principal accounting officer.
The most recent analyst rating on (SMTI) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.
Spark’s Take on SMTI Stock
According to Spark, TipRanks’ AI Analyst, SMTI is a Neutral.
Sanara MedTech’s overall stock score reflects its strong revenue growth and product sales expansion, which are significant positives. However, these are balanced by ongoing concerns in profitability, cash flow management, and increased leverage. The technical analysis suggests neutral market momentum, and the valuation is challenged by negative earnings. The earnings call highlights both growth opportunities and financial challenges, shaping a mixed overall outlook.
To see Spark’s full report on SMTI stock, click here.
More about Sanara MedTech
Average Trading Volume: 28,143
Technical Sentiment Signal: Sell
Current Market Cap: $275.4M
For detailed information about SMTI stock, go to TipRanks’ Stock Analysis page.